A Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back - Full Text View

Sponsor:	Meda Pharmaceuticals
Information provided by:	Meda Pharmaceuticals
ClinicalTrials.gov Identifier:	NCT00671502

Purpose

The purpose of this study is to determine if two sustained released formulations of carisoprodol are more effective than placebo.

Condition	Intervention	Phase
Lower Back Pain	Drug: Carisoprodol Drug: Carisoprodol SR Drug: Placebo	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	Randomized, Double-Blind, Double-Dummy Trial of Two Sustained Release Formulations of Carisoprodol Compared to Placebo in Subjects With Acute, Painful, Musculoskeletal Spasm of the Lower Back

Resource links provided by NLM:

MedlinePlus related topics: Back Pain

Drug Information available for: Carisoprodol

U.S. FDA Resources

Further study details as provided by Meda Pharmaceuticals:

Primary Outcome Measures:

Subject rating of pain on a 100-point visual analog scale (VAS) [ Time Frame: up to 14 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Subject functional assessment based on the Roland-Morris Disability Questionnaire (RMDQ) [ Time Frame: up to 14 days ] [ Designated as safety issue: No ]
Adverse events assessments [ Time Frame: up to 21 days ] [ Designated as safety issue: Yes ]

Estimated Enrollment:	840
Study Start Date:	April 2008
Study Completion Date:	February 2009
Primary Completion Date:	February 2009 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Carisoprodol 700mg: Experimental	Drug: Carisoprodol 700 mg twice daily
Carisoprodol 500mg: Experimental	Drug: Carisoprodol SR 500 mg twice daily
Placebo: Placebo Comparator	Drug: Placebo Placebo

Eligibility

Ages Eligible for Study:	18 Years to 70 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Onset of pain is within 3 days of first visit
Subject rating of pain must be 40 mm or greater on VAS
Ability to discontinue all analgesics, NSAIDs, and other muscle relaxants
Willingness to provide written informed consent
Must be in generally good health

Exclusion Criteria:

Presence of sciatic pain
History of clinically significant spine pathology such as herniated nucleas pulposis, spondylolisthesis, spinal stenosis
Presence of underlying chronic back pain
Neurological signs and symptoms such as numbness, tingling, foot drop, parethesia, unexplained constipation, urinary retention or urinary incontinence
Myocardial infaction within one year of study
Cancer not in remission or in remission less than one year
HIV or other immunodeficiency syndromes
History of osteoporosis or at high risk for vetebral fracture
Underlying rheumatologic disease such as rheumatoid arthritis, ankylosing spondylitis, etc.
Presence of active influenze or other viral syndromes
Morbid obesity (BMI >39)
Evidence of infection, such as low grade fever or neutrophilia
Existence of any medical/surgical condition that could interfere with the evaluation of the study medication
Known history of alcohol or drug abuse
Injury involving high potential for litigation, including worker's compensation or automobile accidents
Pregnancy or breast feeding
Women of child-bearing potential not abstinent or not practicing a medically acceptable method of contraception
Vertebral body or spinous process, percussive tenderness on physical exam
Any abnormalities in the following tests of both lower extremities: ankle dorsiflexion strength, great toe dorsiflexion strength, absent or hypereflexic Achilles or patellar tendor reflexes, abnormal sensory exam in the medial, dorsal or lateral aspect of the foot and positive straight leg raise test
Urgent medical conditions on comprehensive exam that might indicate a more serious condition should be treated urgently

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00671502

Show 68 Study Locations

Sponsors and Collaborators

Meda Pharmaceuticals

Investigators

Study Director:

Lewis M. Fredane, MD

Meda Pharmaceuticals

More Information

No publications provided

Responsible Party:	Meda Pharmaceuticals ( Harry Sacks, MD Vice President, Medical and Scientific Affairs )
Study ID Numbers:	MP510
Study First Received:	May 1, 2008
Last Updated:	April 30, 2009
ClinicalTrials.gov Identifier:	NCT00671502 History of Changes
Health Authority:	United States: Food and Drug Administration

Additional relevant MeSH terms:

Carisoprodol
Nervous System Diseases
Physiological Effects of Drugs
Low Back Pain
Pain
Neuromuscular Agents
Back Pain

Pharmacologic Actions
Signs and Symptoms
Therapeutic Uses
Muscle Relaxants, Central
Neurologic Manifestations
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on February 08, 2010